puff), or placebo in random order on five separate days. Doses were administered by a metered dose inhaler at intervals of 60 minutes to give cumulative doses oftwo, six, 14 , and 30 puffs. Five mg of nebulised salbutamol was administered 60 minutes after the patient had received the final 16 puffs of each regimen. Forced expiratory volume in one second (FEVI), forced vital capacity (FVC), heart rate, and blood pressure were measured five minutes before each treatment and 30 minutes after treatment with nebulised salbutamol. Results -FEV1 and FVC reached a plateau after administration of a cumulative dose of 14 puffs ofipratropium bromide (280 tg) or flutropium bromide (420 tg), and after six puffs of oxitropium bromide (600 ,sg).
There were no differences with respect to maximum increases in FEVy and FVC amongst the three anticholinergic agents. However, after six puffs oxitropium bromide produced a greater increase in FEVy than either ipratropium bromide or flutropium bromide. Fenoterol caused a greater increase in both FEV, and FVC than the three anticholinergic agents after six puffs, as well as a greater increase in pulse rate. Oxitropium bromide produced a greater increase in pulse rate than the other anticholinergics after 14 puffs. The incidence of side effects was dose-related and notable adverse effects were reported after 30 puffs of ipratropium bromide, 14 puffs ofoxitropium bromide, and two puffs of fenoterol.
Conclusions -Oxitropium bromide produced a greater bronchodilator effect than either ipratropium bromide or flutropium bromide when used at doses of less than six puffs, without apparent side effects. There were, however, no differences in maximal response between these drugs. Fenoterol may have a greater peak bronchodilator effect than the anticholinergic agents but it causes more adverse effects, even at lower doses. Depending upon the balance between efficacy and side effects, oxitropium bromide may be preferred in the treatment of patients with COPD. Five mg of nebulised salbutamol in 1 ml saline was administered 60 minutes after the patient had received 16 puffs of each regimen. Spirometric testing was performed initially, 60 minutes after each dose (and just before the administration of the next dose), and 30 minutes after the administration of nebulised salbutamol. Pulse rate and blood pressure were also measured after at least five minutes of rest before each spirometric measurement. Simultaneously, patients were asked to note any side effects such as dryness of the mouth, dysuria, palpitations, or tremor. If the patient developed any intolerable side effects, a pulse rate of more than 120 beats per minute, or a systolic blood pressure ofmore than 180 mm Hg before completing the protocol, the study was stopped. Drinks of coffee were not allowed until the study ended. Inhaled bronchodilators were withdrawn for at least 12 hours before the start of each study day.
Each test trial was performed by the same physician (AI), with the subjects taking one puff from the metered dose inhaler every minute. A spacer device, InspireEase, was used in all trials according to the technique of Newman et al. " The metered dose inhaler with attached spacer was held in the mouth. After the patient had exhaled to functional residual capacity, the canister was activated. Patients then inhaled very slowly until total lung capacity was reached, at which point the breath was held for at least 10 seconds. To ensure that the trials were double blind, identical metered dose inhaler canisters containing either active drug or placebo were prepared in advance, coded, and randomly selected. The treatment codes were not revealed until all 20 patients had completed the protocols.
Spirometric testing was performed according to the methods described in the American Thoracic Society's 1987 update.14 Three consecutive flow-volume curves were recorded with a spirometer (AUTOSPIRO AS-600, Minato Medical Science, Osaka, Japan), which was precalibrated with a 3-01 syringe before each day oftesting. The highest FEV, and FVC from the triplicate measurements were analysed and predicted FEV1 and FVC values were calculated according to the 1993 proposal of the Japan Society of Chest Diseases."5 Pulmonary function tests were performed within the three months preceding the study and at least 12 hours after the administration of bronchodilators had been suspended. In addition to spirometric testing (CHESTAC-65V, Chest, Tokyo, Japan) the functional residual capacity was measured by plethysmography (MBR-600, Nihon Kohden, Tokyo, Japan) and this was combined with the inspiratory capacity measured spirometrically to calculate the total lung capacity. The static compliance and airways resistance were also measured by plethysmography. The carbon monoxide diffusing capacity was measured using the single breath technique (CHESTAC-65V).
DATA ANALYSIS
Friedman's two way analysis of variance was used to compare differences between the five test regimens with respect to FEVy and FVC (expressed as absolute changes from the baseline), and also with respect to pulse rate and blood pressure (expressed as absolute differences relative to the placebo). When a significant difference existed among groups the Wilcoxon signed rank test was used to identify specifically which differences were significant. Categoric variables were compared using the x2 test. Data for analyses were expressed as means (SE) and a probability level of less than 5% (two tailed) was considered significant.
Results
All 20 patients completed the protocol using the three anticholinergic agents and the placebo. In the trial using fenoterol, however, four patients withdrew after a cumulative dose of 14 puffs and eight patients after 30 puffs because of severe tremor and palpitations. Statistical comparisons between the effects of fenoterol and the anticholinergics were therefore carried out only at doses of two and six puffs.
Baseline clinical data are shown in table 1. The average patient was elderly with relatively fig 3. Fenoterol caused a significant dose-related increase in pulse rate, greater then the anticholinergic agents up to a dose of six puffs. Oxitropium bromide also caused a significant dose-related increase in pulse rate which was greater than the other anticholinergics after 14 puffs or more. No significant changes were recorded after treatment with ipratropium bromide or flutropium bromide. There were no significant differences among the four treatment groups in blood pressure changes when compared with the placebo group.
Oxitropium bromide caused a greater increase in the incidence of oral dryness after 14 puffs, and of dysuria after 30 puffs, than the other drugs (p<0 05). Ipratropium bromide caused a greater increase in the incidence oforal dryness after 30 puffs than placebo (p<0-05). Flutropium bromide did not cause significantly more side effects than placebo. Fenoterol caused a greater increase in the incidence of tremor at each dose, and of palpitations at doses of more than six puffs, than any of the other drugs (p<005) (table 3) .
Discussion
The present study has shown that the dose needed to produce near maximal bronchodilation was seven times higher than that recommended for both ipratropium bromide and flutropium bromide, and three times that for oxitropium bromide. This result is even more significant considering that the drugs had equal efficacy. Very few studies have attempted to determine the optimal dose of bronchodilators in patients with COPD, although evidence suggests that therapeutic dosages of ipratropium bromide or oxitropium bromide may be suboptimal in COPD."7 '0 Since penetration of inhaled particles into the airways is impaired when the airways are obstructed, higher than recommended dosages of bronchodilators may be needed for a maximal effect in patients with severe airways obstruction.'617
In previous studies in which bronchodilator effects have been assessed using a metered dose inhaler with the InspirEase spacer in patients with COPD, the peak effect of ipratropium Since fenoterol is currently marketed at a higher dose per puff than other , agonists,26 it might be expected to produce greater benefits, but it may also cause more side effects and can hardly be recommended as the drug of choice in the treatment of COPD.
In conclusion, oxitropium bromide produced significantly greater bronchodilator effects than either ipratropium bromide or flutropium bromide when used in doses of less than six puffs, without apparent side effects. Although maximal bronchodilator effects were similar for all three anticholinergics, oxitropium bromide may be the most useful drug in clinical practice for the treatment of patients with COPD.
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